Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.glenmarkpharma.com | |
Market Cap | 22,175.60 Cr. | |
Enterprise Value(EV) | 25,053.62 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 9.02 | Trailing Twelve Months Ending 2023-06 |
Price-Earning Ratio (PE) | 87.08 | Trailing Twelve Months Ending 2023-06 |
Industry PE | 37.43 | Trailing Twelve Months Ending 2023-06 |
Book Value / Share | 341.27 | Trailing Twelve Months Ending 2023-06 |
Price to Book Value | 2.30 | Calculated using Price: 785.90 |
Dividend Yield | 0.32 | Period Ending 2023-03 |
No. of Shares Subscribed | 28.22 Cr. | 282,168,156 Shares |
FaceValue | 1 | |
About Glenmark Pharmaceuticals Ltd. | ||
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark's formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. |
1 Day |
|
-2.04% |
1 Week |
|
-8.19% |
1 Month |
|
+3.53% |
3 Month |
|
+25.27% |
6 Month |
|
+80.11% |
1 Year |
|
+102.53% |
2 Year |
|
+53.54% |
5 Year |
|
+19.96% |
10 Year |
|
+49.65% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 8.79 | 27.46 | 27.31 | 16.67 | 17.21 | 13.32 | 14.81 | 12.33 | 4.07 | |
Return on Capital Employed (%) | 12.40 | 18.53 | 20.54 | 14.77 | 16.47 | 14.04 | 15.30 | 14.19 | 9.17 | |
Return on Assets (%) | 2.58 | 8.52 | 11.33 | 7.40 | 7.98 | 6.17 | 7.11 | 6.74 | 2.29 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Shh. Funds | 2,983 | 1,783 | 3,630 | 4,493 | 5,163 | 5,605 | 6,071 | 7,065 | 9,087 | 9,474 | |
Non Curr. Liab. | 1,967 | 2,749 | 1,499 | 3,258 | 2,824 | 2,280 | 3,033 | 2,804 | 1,270 | 2,681 | |
Curr. Liab. | 2,949 | 3,777 | 3,999 | 2,703 | 3,288 | 4,021 | 4,126 | 4,201 | 4,689 | 5,046 | |
Minority Int. | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 351 | 365 | |
Equity & Liab. | 7,912 | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 17,566 | |
Non Curr. Assets | 3,150 | 2,978 | 3,224 | 3,578 | 4,286 | 5,209 | 6,425 | 6,709 | 7,115 | 7,692 | |
Curr. Assets | 4,763 | 5,331 | 5,904 | 6,875 | 6,989 | 6,697 | 6,804 | 7,360 | 8,282 | 9,874 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 7,912 | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 17,566 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
Net Sales | 6,681 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 13,614 | |
Other Income | 7 | 20 | 37 | 91 | 208 | 160 | 50 | 167 | 317 | 155 | |
Total Income | 6,688 | 7,582 | 9,117 | 9,166 | 10,074 | 10,801 | 10,994 | 12,472 | 13,307 | 13,769 | |
Total Expenditure | -5,467 | -6,125 | -7,043 | -7,459 | -8,280 | -8,943 | -8,860 | -9,985 | -10,712 | -11,136 | |
PBIDT | 1,221 | 1,457 | 2,074 | 1,707 | 1,794 | 1,858 | 2,135 | 2,487 | 2,595 | 2,632 | |
Interest | -190 | -179 | -237 | -286 | -335 | -377 | -353 | -298 | -350 | -402 | |
Depreciation | -300 | -234 | -264 | -302 | -326 | -417 | -444 | -487 | -611 | -619 | |
Taxation | -334 | -301 | -383 | -315 | -376 | -320 | -412 | -448 | -491 | -454 | |
Exceptional Items | -187 | -81 | 167 | 33 | 45 | -261 | -766 | -818 | |||
PAT | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | 339 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -52 | -80 | -85 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 210 | 743 | 1,109 | 804 | 925 | 776 | 970 | 942 | 297 | 255 | |
Adjusted EPS | 8 | 26 | 39 | 28 | 33 | 28 | 34 | 33 | 11 | 9 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 854 | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | |
Cash Fr. Inv. | -368 | -540 | -880 | -712 | -1,013 | -699 | -784 | -675 | -333 | -528 | |
Cash Fr. Finan. | -98 | 199 | 699 | 543 | -469 | -739 | -445 | -442 | -520 | -77 | |
Net Change | 388 | 141 | 163 | 488 | 166 | -114 | 164 | 14 | 255 | 19 | |
Cash & Cash Eqvt | 795 | 764 | 857 | 1,056 | 1,233 | 936 | 1,110 | 1,138 | 1,411 | 1,443 |
Sat, 23 Sep 2023
Announcement under Regulation 30 (LODR)-Credit Rating India Ratings has discontinued and withdrawn the outstanding voluntary issuer ratings disclosure due to regulatory requirements. |
Fri, 22 Sep 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Details of Analyst/ Investors Meeting is attached |
Thu, 21 Sep 2023
Clarification sought from Glenmark Pharmaceuticals Ltd The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd on September 21 2023 with reference to news appeared inwww.moneycontrol.com dated September 21 2023 quoting "Glenmark Life Sciences gains on parent Glenmark Pharma plan to pare stake" The reply is awaited. |
Mon, 25 Sep 2023 |
|
|
|
|
|